drugset / Trial / NCT02570373
A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
Timeline
- Start
- 2015-09-25
- Primary completion
- 2016-01-12
- Completion
- 2016-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 10 mg/kg | Intravenous |
Indications
No indication recorded.